Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 169

1.

Randomized controlled trial of annual zoledronic acid to prevent gonadotropin-releasing hormone agonist-induced bone loss in men with prostate cancer.

Michaelson MD, Kaufman DS, Lee H, McGovern FJ, Kantoff PW, Fallon MA, Finkelstein JS, Smith MR.

J Clin Oncol. 2007 Mar 20;25(9):1038-42.

2.

Patient quality of life safeguarding: the primary aim in nonmetastatic prostate cancer patients.

Cai T, Bartoletti R.

J Clin Oncol. 2007 Aug 1;25(22):3385; author reply 3385-6. No abstract available.

PMID:
17664492
3.

Annual zoledronic acid: is less more?

Higano CS.

J Clin Oncol. 2007 Mar 20;25(9):1026. No abstract available.

PMID:
17369565
4.

Randomized controlled trial of zoledronic acid to prevent bone loss in men receiving androgen deprivation therapy for nonmetastatic prostate cancer.

Smith MR, Eastham J, Gleason DM, Shasha D, Tchekmedyian S, Zinner N.

J Urol. 2003 Jun;169(6):2008-12.

PMID:
12771706
5.

Suppression of bone density loss and bone turnover in patients with hormone-sensitive prostate cancer and receiving zoledronic acid.

Ryan CW, Huo D, Bylow K, Demers LM, Stadler WM, Henderson TO, Vogelzang NJ.

BJU Int. 2007 Jul;100(1):70-5.

6.

The effect of zoledronic acid on bone mineral density in patients undergoing androgen deprivation therapy.

Israeli RS, Rosenberg SJ, Saltzstein DR, Gottesman JE, Goldstein HR, Hull GW, Tran DN, Warsi GM, Lacerna LV.

Clin Genitourin Cancer. 2007 Mar;5(4):271-7.

PMID:
17553207
7.

RTOG 0518: randomized phase III trial to evaluate zoledronic acid for prevention of osteoporosis and associated fractures in prostate cancer patients.

Kachnic LA, Pugh SL, Tai P, Smith M, Gore E, Shah AB, Martin AG, Kim HE, Nabid A, Lawton CA.

Prostate Cancer Prostatic Dis. 2013 Dec;16(4):382-6. doi: 10.1038/pcan.2013.35.

8.

Single infusion of zoledronic acid to prevent androgen deprivation therapy-induced bone loss in men with hormone-naive prostate carcinoma.

Satoh T, Kimura M, Matsumoto K, Tabata K, Okusa H, Bessho H, Iwamura M, Ishiyama H, Hayakawa K, Baba S.

Cancer. 2009 Aug 1;115(15):3468-74. doi: 10.1002/cncr.24404.

9.

Frequency of zoledronic acid to prevent further bone loss in osteoporotic patients undergoing androgen deprivation therapy for prostate cancer.

Wadhwa VK, Weston R, Parr NJ.

BJU Int. 2010 Apr;105(8):1082-8. doi: 10.1111/j.1464-410X.2009.08956.x.

10.

Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 5-year follow-up of the ABCSG-12 bone-mineral density substudy.

Gnant M, Mlineritsch B, Luschin-Ebengreuth G, Kainberger F, Kässmann H, Piswanger-Sölkner JC, Seifert M, Ploner F, Menzel C, Dubsky P, Fitzal F, Bjelic-Radisic V, Steger G, Greil R, Marth C, Kubista E, Samonigg H, Wohlmuth P, Mittlböck M, Jakesz R; Austrian Breast and Colorectal Cancer Study Group (ABCSG)..

Lancet Oncol. 2008 Sep;9(9):840-9. doi: 10.1016/S1470-2045(08)70204-3.

PMID:
18718815
12.

Pamidronate to prevent bone loss during androgen-deprivation therapy for prostate cancer.

Smith MR, McGovern FJ, Zietman AL, Fallon MA, Hayden DL, Schoenfeld DA, Kantoff PW, Finkelstein JS.

N Engl J Med. 2001 Sep 27;345(13):948-55.

13.

Post hoc analysis of a single IV infusion of zoledronic acid versus daily oral risedronate on lumbar spine bone mineral density in different subgroups with glucocorticoid-induced osteoporosis.

Roux C, Reid DM, Devogelaer JP, Saag K, Lau CS, Reginster JY, Papanastasiou P, Bucci-Rechtweg C, Su G, Sambrook PN.

Osteoporos Int. 2012 Mar;23(3):1083-90. doi: 10.1007/s00198-011-1800-1.

PMID:
21975559
14.

The use of zoledronic acid in men receiving androgen deprivation therapy for prostate cancer with severe osteopenia or osteoporosis.

Campbell SC, Bhoopalam N, Moritz TE, Pandya M, Iyer P, Vanveldhuizen P, Ellis NK, Thottapurathu L, Garewal H, Warren SR, Friedman N, Reda DJ.

Urology. 2010 May;75(5):1138-43. doi: 10.1016/j.urology.2009.11.083.

PMID:
20303574
15.

Raloxifene to prevent gonadotropin-releasing hormone agonist-induced bone loss in men with prostate cancer: a randomized controlled trial.

Smith MR, Fallon MA, Lee H, Finkelstein JS.

J Clin Endocrinol Metab. 2004 Aug;89(8):3841-6.

PMID:
15292315
16.

Effects of intravenous zoledronic acid plus subcutaneous teriparatide [rhPTH(1-34)] in postmenopausal osteoporosis.

Cosman F, Eriksen EF, Recknor C, Miller PD, Guañabens N, Kasperk C, Papanastasiou P, Readie A, Rao H, Gasser JA, Bucci-Rechtweg C, Boonen S.

J Bone Miner Res. 2011 Mar;26(3):503-11. doi: 10.1002/jbmr.238.

17.

Intravenous zoledronic acid to prevent osteoporosis in a veteran population with multiple risk factors for bone loss on androgen deprivation therapy.

Bhoopalam N, Campbell SC, Moritz T, Broderick WR, Iyer P, Arcenas AG, Van Veldhuizen PJ, Friedman N, Reda D, Warren S, Garewal H.

J Urol. 2009 Nov;182(5):2257-64. doi: 10.1016/j.juro.2009.07.046.

PMID:
19758618
18.

Impact of androgen suppression and zoledronic acid on bone mineral density and fractures in the Trans-Tasman Radiation Oncology Group (TROG) 03.04 Randomised Androgen Deprivation and Radiotherapy (RADAR) randomized controlled trial for locally advanced prostate cancer.

Denham JW, Nowitz M, Joseph D, Duchesne G, Spry NA, Lamb DS, Matthews J, Turner S, Atkinson C, Tai KH, Gogna NK, Kenny L, Diamond T, Smart R, Rowan D, Moscato P, Vimieiro R, Woodfield R, Lynch K, Delahunt B, Murray J, D'Este C, McElduff P, Steigler A, Kautto A, Ball J.

BJU Int. 2014 Sep;114(3):344-53. doi: 10.1111/bju.12497.

19.

A randomized phase II trial evaluating different schedules of zoledronic acid on bone mineral density in patients with prostate cancer beginning androgen deprivation therapy.

Lang JM, Wallace M, Becker JT, Eickhoff JC, Buehring B, Binkley N, Staab MJ, Wilding G, Liu G, Malkovsky M, McNeel DG.

Clin Genitourin Cancer. 2013 Dec;11(4):407-15. doi: 10.1016/j.clgc.2013.04.029.

20.

Randomized, double-blinded, placebo-controlled, trial of risedronate for the prevention of bone mineral density loss in nonmetastatic prostate cancer patients receiving radiation therapy plus androgen deprivation therapy.

Choo R, Lukka H, Cheung P, Corbett T, Briones-Urbina R, Vieth R, Ehrlich L, Kiss A, Danjoux C.

Int J Radiat Oncol Biol Phys. 2013 Apr 1;85(5):1239-45. doi: 10.1016/j.ijrobp.2012.11.007.

PMID:
23265571
Items per page

Supplemental Content

Support Center